>>couple of thoughts that spring to my mind
1. Would a future phase 3 go on backbone of gem/abraxane or folfirinx?
2. It seems unlikely they’d be able run a phase 3 alone and raise enough capital here. A phase 3 sized for survival if that’s the expected endpoint could be a beast. (The mpact trial size was >850, the napoli3 trial was nearly 800).
>>Getting ahead of myself probably but it got me thinking.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-23
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
0.001(1.06%) |
Mkt cap ! $26.10M | |||
| Open | High | Low | Value | Volume |
| 9.5¢ | 10.0¢ | 9.4¢ | $22.98K | 240.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 146804 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 52046 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |